Compare Citius Pharmaceuticals Inc (CTXR) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs MakeMyTrip Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while MakeMyTrip Ltd trades at $55.95 (market cap $5.29B). The key difference: MakeMyTrip Ltd is far larger — about 361.3× Citius Pharmaceuticals Inc's market cap, and MakeMyTrip Ltd is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | MMYT | |
|---|---|---|
Market Cap | $14.64M | $5.29B |
Sector | Health | Technology |
52-Week High | $1.82 | $103.21 |
52-Week Low | $0.53 | $36.30 |
Enterprise Value | $10.86M | $5.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
MakeMyTrip (MMYT) trades at $57.08, down 2.63% today but maintains a bullish technical outlook with strong analyst support. The company demonstrates robust fundamentals with $978M revenue and $95M net income for 2025, though 2026 projections show margin compression. Recent earnings beats and a 73% gross margin highlight operational strength, while technical indicators show bullish moving averages despite recent price weakness.
The stock presents a compelling growth opportunity with strong analyst consensus (73% buy ratings) and consistent earnings outperformance. However, elevated P/E ratio (154.86) and projected margin pressure in 2026 warrant caution. Key risks include travel industry volatility and rising debt-to-asset ratio from 12% to 81% projected for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
